BNC 1501
Alternative Names: BNC-1501Latest Information Update: 02 Apr 2023
At a glance
- Originator BONAC Corporation
- Class Antineoplastics; Nucleic acids; RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Mar 2023 Discontinued - Preclinical for Cancer in Japan (BONAC Corporation pipeline, March 2023)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Cancer in Japan
- 28 Jan 2019 BONAC Corporation has patent protection for Bonac Nucleic Acid (substance patent) (BONAC Corporation website, January 2019)